MedTrace Logo

Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)

NCT04102930 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4500

Last updated 2025-03-30

No results posted yet for this study

Summary

A multi-centre observational study recruiting prospective and retrospective cohorts of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). The primary aim is to find genetic determinants of GCA and PMR susceptibility, in order to yield novel insights into disease pathogenesis. A subset of the retrospective cohort is also enrolled in a post-marketing surveillance registry of patients eligible for, or receiving tocilizumab, to treat their relapsing or refractory GCA.

Conditions

  • Giant Cell Arteritis
  • Polymyalgia Rheumatica

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • University of Leeds

    lead OTHER

Principal Investigators

  • Ann Morgan · University of Leeds

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-10
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04102930 on ClinicalTrials.gov